Clinical Trials
13
Active:0
Completed:4
Trial Phases
4 Phases
Phase 1:5
Phase 2:2
Phase 3:4
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials
Phase 1
5 (38.5%)Phase 3
4 (30.8%)Not Applicable
2 (15.4%)Phase 2
2 (15.4%)Study of SYH2062 Injection in Healthy Chinese Volunteers
Phase 1
Recruiting
- Conditions
- Healthy Chinese Volunteers
- Interventions
- Drug: SYH2062 injectionDrug: SYH2062-Matching placebo
- First Posted Date
- 2025-02-24
- Last Posted Date
- 2025-04-30
- Target Recruit Count
- 46
- Registration Number
- NCT06842537
- Locations
- 🇨🇳
Chinese Academy of Medical Science and Peking Union Medical College Hospital, Beijing, Beijing, China
Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and Vomiting
Phase 3
Not yet recruiting
- Conditions
- Post-operative Nausea and Vomiting (PONV)
- Interventions
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-08-09
- Target Recruit Count
- 486
- Registration Number
- NCT06543966
A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2053
- First Posted Date
- 2024-01-29
- Last Posted Date
- 2025-04-04
- Target Recruit Count
- 39
- Registration Number
- NCT06229548
- Locations
- 🇨🇳
10 Chedaogou Rd.,Haidian District, Beijing, China, Beijing, Beijing, China
A Bridging Study of Liposomal Cytarabine-Daunorubicin in Treating Olderly Patients With Treatment-naive High-Risk (Secondary) Acute Myeloid Leukemia
Phase 3
Not yet recruiting
- Conditions
- High-risk (Secondary) Acute Myeloid Leukemia
- Interventions
- Drug: Liposomal cytarabine-daunorubicin for injectionDrug: 7+3 (cytarabine and daunorubicin)
- First Posted Date
- 2023-12-27
- Last Posted Date
- 2023-12-28
- Target Recruit Count
- 120
- Registration Number
- NCT06182592
- Locations
- 🇨🇳
Institute of Hematology and Hospital of Blood Disease, Chinese Academy of Medical Sciences, Tianjin, China
Bioequivalence of Amphotericin B Liposome for Injection
Phase 1
Completed
- Conditions
- Bioequivalence
- Interventions
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2023-09-28
- Target Recruit Count
- 32
- Registration Number
- NCT05913921
- Locations
- 🇨🇳
Haikou people's Hospital, Haikou, Hainan, China
- Prev
- 1
- 2
- 3
- Next
News
No news found